{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred', 'lifestyle (abstinent on a long term and persistent basis) and agree to remain', 'abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Female participants', 'Female participants of childbearing potential are eligible to participate if they agree to', 'use a highly effective method of contraception consistently and correctly as described in', 'Table 6.', 'Table 9', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', '91']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', 'Amended text:', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's review of participant's\", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level', 'in the postmenopausal range may be used to confirm a postmenopausal', 'state in women not using hormonal contraception or hormonal', 'replacement therapy (HRT). However, in the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient and confirmatory', 'testing with additional FSH and estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be', 'required to use one of the non-hormonal highly effective contraception', 'methods if they wish to continue their HRT during the study. Otherwise,', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', '92']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred', 'lifestyle (abstinent on a long term and persistent basis) and agree to remain', 'abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Table 10', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', '93']\n\n###\n\n", "completion": "END"}